

FORM PTO-1449  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MAXIM.078A	APPLICATION NO. 09/616,622
O I P E INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (USE SEVERAL SHEETS IF NECESSARY)		AUG 17 2001
APPLICANT Hellstrand et al.		
FILING DATE 07/14/00		GROUP 1644-1644 TECH CENTER 1600/2900

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

**EXAMINER  
INITIAL**

**OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)**

- Gerami-Nejad et al. (1981) Aspects of the antibacterial action of diphenyliodonium chloride. *Microbios*. 30:97-107.

S:\DOCS\JJM\JJM-6454.DOC\080301

EXAMINER <u>E. Wacht</u>	DATE CONSIDERED <u>11/14/01</u>
--------------------------	---------------------------------

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. MAXIM.078A	APPLICATION NO. 09/616,622
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		NOV 29 2000 PATENT & TRADEMARK OFFICE	
(USE SEVERAL SHEETS IF NECESSARY)		FILING DATE July 14, 2000	GROUP 1644

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)	
<i>[Signature]</i>	1 5,348,739	09/20/94					

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO


EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)						
	2	Alderson et al. (1995) Fas ligand mediates activation-induced cell death in human T lymphocytes. J.Exp.Med. 181:71-77.					
	3	Allen et al. (1997) Morphological and biochemical characterization and analysis of apoptosis. JPM. 37:4:215-228					
	4	Armstrong et al. (1998) Tumor antigen presentation: changing the rules. Cancer Immunol Immunother. 46:70-74					
	5	Barna et al. (1983) Tumor-Enhancing effects of cimetidine. Oncology. 40:43-45.					
	6	Bauer et al. (1998) Role of reactive oxygen intermediates in activation-induced CD95 (APO-1/Fas) ligand expression. J.Bio.Chem. 273:14:8048-8055.					
	7	Barhoumi et al. (1993) concurrent analysis of intracellular glutathione content and gap junctional intercellular communication. Cytometry. 14:747-756.					
	8	Becker et al. (1996) T Cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J.Exp.Med. 183:2361-66.					
	9	Beggins et al. (1998) Variable expression of CD3-zeta and associated protein tyrosine kinases in lymphocytes from patients with myeloid malignancies. British J. of Haematology. 100:784-792.					
	10	Bottazzi et al. (1992) Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility of IL-2 therapy of a murine melanoma <sup>1</sup> . J.of Immuno. 148:1280-1285.					
	11	Brunda et al. (1987) In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling nature killer cells. Int.J.Cancer. 40:365-371.					
	12	Brune et al. (1996) Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia. British J. of Haematology. 92:620-626.					
	13	Birtin et al. (1981) The influence of intraperitoneal injections of histamine on tumour growth in fibrosarcoma-bearing mice. Cancer letters. 12:195-201.					
	14	Buttke et al. (1994) Oxidative stress as a mediator of apoptosis. Immunology Today. 15:1:7-10.					
	15	Cao et al. (1998) Interleukin 15 protecgs against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer. Cancer Reserach. 58:1695-1699.					
	16	Dohilstens et al. (1986) Synergistic action of gamma interferon and catalase to reverse the suppressive effect of peritoneal macrophages on concanavalin A-induced lymphocyte proliferation. Scand.J.Immunol. 24:49-58.					
	17	Dröge et al. (1994) Functions of glutathione and glutathione disulfide in immunology and immunopathology. The FASEB Journal. 8:1131-1138.					
	18	Dumont et al. (1999) Hydrogen peroxide-induced apoptosis is CD95-independent, requires the release of mitochondria-derived reactive oxygen species and the activation of NF- $\kappa$ B. Oncogene. 18:747-757.					
<i>[Signature]</i>	19	Dutcher et al. (1989) A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J.of clin.Onc. 7:4:477-485.					

EXAMINER	<i>Elliott</i>	DATE CONSIDERED	11/14/01
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. MAXIM.078A	APPLICATION NO. 09/616,622
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		P A T E N T & T R A D E M A R K O F F I C E	
(USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Hellstrand, et al.	
		FILING DATE July 14, 2000	GROUP <del>1644</del> 1641

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
582	20 Fao et al. (1991) Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: a pilot study. British J. of Haematology. 77:491-496.
	21 Hansson et al. (1996) Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. J. of Immuno. 42:47.
	22 Hawkins, M.J. (1993) Interleukin-2 antitumor and effector cell responses. Seminars in Oncology. 20:6:52-59.
	23 Hellstrand et al. (1986) Histamine h2-receptor-mediated regulation of human natural killer cell activity. J.of Immuno. 137:2:656-660.
	24 Hellstrand et al. (1990) Synergistic activation of human natural killer cell cytotoxicity by histamine and interleukin-2. Int.Arch.Allergy App. Immuno. 92:379-389.
	25 Hellstrand et al. (1990) Role of histamine in natural killer cell-mediated resistance against tumor cells. J.of Immuno. 145:4365-4370.
	26 Hellstrand et al. (1991) Monocyte-induced down-modulation of CD16 and CD56 antigens on human natural killer cells and its regulation by histamine H2-receptors. Cellular Immuno. 138:44-54.
	27 Hellstrand et al. (1994) Histaminergic regulation of antibody-dependent cellular cytotoxicity of granulocytes, monocytes, and natural killer cells. J. of Leukocyte Biology. 55:392-397.
	28 Hellstrand et al. (1994) Histaminergic regulation of NK cells. J. of Immuno. 153:4940-4947.
	29 Hellstrand et al. (1994) Histamine in immunotherapy of advanced melanoma: a pilot study. Cancer Immuno.Immunother. 39:416-419.
	30 Hellstrand et al. (1995) Role of histamine in natural killer cell-dependent protection against herpes simplex virus type 2 infection in mice. Clin.Diagn.Lab.Immunol. 2:3:277-280.
	31 Hellstrand et al. (1997) Histamine and interleukin-2 in acute myelogenous leukemia. Leukemia and Lymphoma. 27:429-438.
	32 Johansson et al. (1998) The response of dunning R3327 prostatic adenocarcinoma to IL-2, histamine and radiation. British J. of Cancer. 77:8:1213-1219.
	33 Klebanoff, S.J. hydrogen-dependent cytotoxic mechanisms of phagocytes. Advances in Host Defense Mechanisms. 1:111-162.
	34 Kono et al. (1996) Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur.J.Immunol. 26:1308-1313.
	35 Lanier et al. (1988) Interleukin 2 activation of natural killer cells rapidly induces the expression and phosphorylation of the leu-23 activation antigen. J.Exp.Med. 167:1572-1585.
	36 Linden et al. (1987) Catalase and lipopolysaccharide enhance proliferation in the rat mixed lymphocyte reaction. Scand.J.Immunol. 26:223-228.
	37 Lundqvist et al. (1996) Isoluminol-enhanced chemiluminescence: a sensitive method to study the release of superoxide anion from human neutrophils. Free Radical Biology & Medicine. 20:6:785-792.
	38 Mantovani et al. (1992) The origin and function of tumor-associated macrophages. Immunology Today. 13:7:265-270.
	39 Matsuda et al. (1995) Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int.J.Cancer. 61: 765-772.
	40 Medvediv et al. (1997) Regulation of fas and fas-ligand expression in NK cells by cytokines and the involvement of fas-ligand in NK/LAK cell-mediated cytotoxicity. Cytokine. 9:6:394-404.
	41 Miesel et al. (1996) Suppression of inflammatory arthritis by simultaneous inhibition of nitric oxide synthase and nadph oxidase. Free Radical Biology & Medicine. 20:1:75-81.
	42 Mizoguchi et al. (1992) Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science. 258:1795-1798.
	43 Motzer et al. (1998) Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clinical Cancer Research. 4:1183-1191.
	44 Nordlund et al. (1983) The effect of histamine, antihistamines, and a mast cell stabilizer on the growth of claudman melanoma cells in DBA/2 mice. J. of Investigative Dermatology. 81:1:28-31.
	45 Osband et al. (1981) Successful tumour immunotherapy with cimetidine in mice. The Lancet. 636-638.
9542	46 Otsuji et al. (1996) Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 $\zeta$ chain of T-cell receptor complex and antigen-specific T-cell responses. Proc.Ntl.Acad.Sci. 93:13119-13124.

EXAMINER <i>Eurd</i>	DATE CONSIDERED <i>11/14/01</i>
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449      U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MAXIM.078A 	APPLICATION NO. 09/616,622
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		
(USE SEVERAL SHEETS IF NECESSARY)		
APPLICANT Hellstrand, et al.		
FILING DATE July 14, 2000		GROUP 1614 <i>1644</i>

S:\DOCS\JJM\JJM-5079.DOC\112700

EXAMINER	<i>Ewalt</i>	DATE CONSIDERED	11/14/01
----------	--------------	-----------------	----------

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.